ISSN 2756-3340
African Journal of Infectious Diseases Research | Vol. 13, No. 11, November 2026 | pp. 948–955
DOI: 10.46882/AJIDR/149036
Article Type: Research Article
Title: Molecular surveillance and fexinidazole treatment outcomes in second-stage Trypanosoma brucei gambiense human African trypanosomiasis
Names of Authors: Jean-Paul Kabongo¹*, Astrid Lindberg², Rajesh Nair³
Abstract: Gambiense human African trypanosomiasis is a fatal vector-borne protozoan disease targeting the central nervous system if left untreated during the hemolymphatic stage. We assessed diagnostic sensitivity of loop-mediated isothermal amplification, cerebrospinal fluid white cell counts, and oral fexinidazole cure rates. Blood and cerebrospinal fluid specimens from 94 seropositive patients were examined at baseline and 12 months post-treatment. Oral fexinidazole achieved a 92.6 percent treatment success rate in late-stage disease without requiring routine lumbar puncture in non-severe presentations. All-oral therapy accelerates sleeping sickness elimination.
Keywords: Trypanosoma brucei gambiense, African trypanosomiasis, Fexinidazole, Neglected tropical diseases, Protozoan infections
Citation: Kabongo J, Lindberg A, Nair R (2026). Molecular surveillance and fexinidazole treatment outcomes in second-stage Trypanosoma brucei gambiense human African trypanosomiasis. African Journal of Infectious Diseases Research, 13(11): 948–955. DOI: 10.46882/AJIDR/149036
Manuscript Timeline: Received: October 11, 2026; Revised: November 10, 2026; Accepted: November 26, 2026; Published: November 30, 2026
Subscribe to read the full article: https://mail.internationalscholarsjournals.org/subscribe-to-read